A new systematic review and meta-analysis published in BMC Cardiovascular Disorders has identified the cancer antigen 125 (CA125) as a promising biomarker for heart failure (HF). This antigen was traditionally used in ovarian cancer detection. Data for this study were pooled from 29 studies and over 20,000 patients. It was found that elevated CA125 levels were consistently associated with worse outcomes, including higher all-cause and cardiovascular mortality, more frequent hospitalizations, and greater symptom burden, such as pleural effusion and advanced New York Heart Association (NYHA) class.

Compared to biomarkers like NT-proBNP, CA125 showed moderate correlation (r = 0.42) but offered distinct advantages. Notably, it was reliable in reflecting systemic congestion and right-sided heart failure, while being less affected by age and renal impairment. Importantly, several studies demonstrated that CA125 provided prognostic value even in patients with normal NT-proBNP levels, suggesting a complementary role in risk stratification.

The CHANCE-HF trial demonstrated that CA125-guided diuretic adjustment reduced hospital readmissions and improved renal outcomes, while NT-proBNP–guided therapy showed no such benefit. Additionally, serial measurements of CA125 during hospitalization or follow-up were better predictors of long-term outcomes than single baseline readings.

Although CA125 shows some promising benefits, it also has certain limitations. CA125 levels can rise in non-cardiac conditions such as cirrhosis or malignancy, and heterogeneity in cut-off values across studies complicates standardization. Further research is needed to confirm the role of CA123 in HF management. If these limitations can be mitigated, this biomarker could refine prognosis, guide therapy, and ultimately improve care for millions living with heart failure worldwide.